{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:46:34Z","timestamp":1790142394270,"version":"4.0.1"},"reference-count":104,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Carbapenem-resistant Acinetobacter baumannii infections pose a significant challenge due to their severity and the poor prognoses they often result in, particularly in cases where there are risk factors present. The United States (US) Centers for Disease Control and Prevention (CDC) identified carbapenem-resistant Acinetobacter baumannii (CRAB) infections as a threat to human health. The World Health Organization (WHO) has classified it as a top priority for research. In 2023, the US FDA approved sulbactam\u2013durlobactam for treating certain A. baumannii infections. As of 2024, this combination is designated as the preferred treatment strategy by the Infectious Diseases Society of America (IDSA) for infections due to carbapenem-resistant A. baumannii. In this therapeutic review, the preclinical and clinical data relevant to this regulatory decision were analyzed. This in-depth analysis will provide a comprehensive overview of the complex subject matter. It should be observed that carbapenem-based combination therapy is indicated for carbapenem-resistant A. baumannii.<\/jats:p>","DOI":"10.3390\/pathogens15040449","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:42:45Z","timestamp":1776771765000},"page":"449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sulbactam\u2013Durlobactam for Carbapenem-Resistant Acinetobacter baumannii\u2013calcoaceticus Complex"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-5360","authenticated-orcid":false,"given":"Francesco","family":"Nappi","sequence":"first","affiliation":[{"name":"Department of Cardiac Surgery, Centre Cardiologique du Nord, 93200 Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0041-1741019","article-title":"Infections Due to Acinetobacter baumannii-calcoaceticus Complex: Escalation of Antimicrobial Resistance and Evolving Treatment Options","volume":"43","author":"Lynch","year":"2022","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Li, Y.J., Pan, C.Z., Fang, C.Q., Zhao, Z.X., Chen, H.L., Guo, P.H., and Zhao, Z.W. (2017). Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: Genetic relationships, risk factors and mortality. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2471-0"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Shi, J., Sun, T., Cui, Y., Wang, C., Wang, F., Zhou, Y., Miao, H., Shan, Y., and Zhang, Y. (2020). Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: A retrospective study in the pediatric intensive care unit. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05321-y"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0197521","DOI":"10.1128\/aac.01975-21","article-title":"Treatment, clinical outcomes, and predictors of mortality among a national cohort of admitted patients with Acinetobacter baumannii infection","volume":"66","author":"Appaneal","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lodise, T.P., Nguyen, S.T., Margiotta, C., and Cai, B. (2025). Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-10749-1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/1469-0691.12363","article-title":"Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: Systematic review and meta-analysis","volume":"20","author":"Lemos","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","article-title":"Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997\u20132016)","volume":"6","author":"Gales","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_9","unstructured":"(2024). Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050. GBD 2021 Antimicrobial Resistance Collaborators. Lancet, 404, 1199\u20131226."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1473-3099(25)00689-9","article-title":"Global burden of lower respiratory infections and aetiologies, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023. GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators","volume":"26","author":"Sirota","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2468-2667(25)00201-4","article-title":"The burden of bacterial antimicrobial resistance in the WHO Eastern Mediterranean Region 1990\u20132021: A cross-country systematic analysis with forecasts to 2050. EMR Antimicrobial Resistance Collaborators","volume":"10","author":"Mestrovic","year":"2025","journal-title":"Lancet Public Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/CCM.0000000000004371","article-title":"Key Takeaways From the U.S. CDC\u2019s 2019 Antibiotic Resistance Threats Report for Frontline Providers","volume":"48","author":"Kadri","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_13","unstructured":"Craig, M. (2026, April 10). CDC\u2019s Antibiotic Resistance Threats Report, Available online: https:\/\/www.hhs.gov\/sites\/default\/files\/michael-craig-cdc-talk-thursday-am-508.pdf."},{"key":"ref_14","unstructured":"(2026, April 10). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240093461."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"FSO395","DOI":"10.2144\/fsoa-2018-0127","article-title":"Accurate identification of clinically important Acinetobacter spp.: An update","volume":"5","author":"Vijayakumar","year":"2019","journal-title":"Future Sci. OA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1574-6968.2006.00195.x","article-title":"The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii","volume":"258","author":"Turton","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e01576-17","DOI":"10.1128\/AAC.01576-17","article-title":"Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel beta-lactamase inhibitor ETX2514 in clinical isolates of Acinetobacter baumannii","volume":"62","author":"McLeod","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/jac\/dkt275","article-title":"TEM-1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii","volume":"68","author":"Krizova","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1099\/jmm.0.45716-0","article-title":"Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones","volume":"53","author":"Nemec","year":"2004","journal-title":"J. Med. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/504477","article-title":"Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa","volume":"43","author":"Bonomo","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","first-page":"3346","article-title":"Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms","volume":"73","author":"Castanheira","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1179\/1973947812Y.0000000029","article-title":"In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates","volume":"24","author":"Deveci","year":"2012","journal-title":"J. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e01268-16","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e01680-20","DOI":"10.1128\/AAC.01680-20","article-title":"Minocycline alone and in combination with polymyxin B, meropenem, and sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model","volume":"65","author":"Beganovic","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Abdul-Mutakabbir, J.C., Yim, J., Nguyen, L., Maassen, P.T., Stamper, K., Shiekh, Z., Kebriaei, R., Shields, R.K., Castanheira, M., and Kaye, K.S. (2021). In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant Acinetobacter baumannii. Antibiotics, 10.","DOI":"10.3390\/antibiotics10070880"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/47.4.479","article-title":"Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains","volume":"47","author":"Cuberos","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: An open-label prospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian. J. Crit. Care Med."},{"key":"ref_29","first-page":"11","article-title":"Triple combination therapy with high-dose ampicillin\/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: A case series study","volume":"27","author":"Assimakopoulos","year":"2019","journal-title":"Infez. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","article-title":"Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis","volume":"24","author":"Liu","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: A systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit. Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"EVIDoa2200131","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial","volume":"57","author":"Signoriello","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol. Infect."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jgar.2018.11.016","article-title":"Colistin monotherapy versus colistin\/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial","volume":"17","author":"Park","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dkq360","article-title":"Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria","volume":"65","author":"Rattanaumpawan","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","article-title":"A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS trial","volume":"151","author":"Kollef","year":"2017","journal-title":"Chest"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","article-title":"Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with gram-negative pneumonia (INHALE): A double-blind, randomised, placebo-controlled, phase 3, superiority trial","volume":"20","author":"Niederman","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1097\/ALN.0b013e3182755d7a","article-title":"Aerosolized antibiotics for ventilator-associated pneumonia: Lessons from experimental studies","volume":"117","author":"Rouby","year":"2012","journal-title":"Anesthesiology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled antibiotics for gram-negative respiratory infections","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Biagi, M., Butler, D., Tan, X., Qasmieh, S., and Wenzler, E. (2019). A breath of fresh air in the fog of antimicrobial resistance: Inhaled polymyxins for gram-negative pneumonia. Antibiotics, 8.","DOI":"10.3390\/antibiotics8010027"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Maselli, D.J., Keyt, H., and Restrepo, M.I. (2017). Inhaled antibiotic therapy in chronic respiratory diseases. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051062"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e0275921","DOI":"10.1128\/mbio.02759-21","article-title":"Carbapenem-resistant Acinetobacter baumannii in U.S. hospitals: Diversification of circulating lineages and antimicrobial resistance","volume":"13","author":"Iovleva","year":"2022","journal-title":"mBio"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cid\/ciad556","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Acinetobacter baumannii among patients from different global regions","volume":"78","author":"Wang","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e0078122","DOI":"10.1128\/aac.00781-22","article-title":"In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"ofac492.1896","DOI":"10.1093\/ofid\/ofac492.1896","article-title":"LB2306. Population pharmacokinetics, pharmacodynamic\/pharmacokinetic attainment and clinical pharmacokinetic\/pharmacodynamic analyses for sulbactam-durlobactam to support dose selection for the treatment of Acinetobacter baumannii-calcoaceticus infections","volume":"9","author":"Bhavnani","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Iovleva, A., Mcelheny, C., Fowler Woods, D., Pradhan, A., Sonnabend, J.L., Matunis, A.R., Raabe, N.J., Lee, J.S., Trevejo-Nu\u00f1ez, G., and Van Tyne, D. (2023). In Vitro Activity of Sulbactam-Durlobactam (SUL-DUR) Against Colistin-Resistant and\/or Cefiderocol-Non-Susceptible, Carbapenem-Resistant Acinetobacter baumannii Collected in US Hospitals, ECCMID.","DOI":"10.1128\/aac.01258-23"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1469-0691.2004.00987.x","article-title":"Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii","volume":"10","author":"Choi","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_52","unstructured":"Tanudra, A., McLeod, S., Miller, A., Tommasi, R., and O\u2019Donell, J. (2022). Sulbactam-Durlobactam (SUL-DUR) In Vitro Dose Response Studies With and Without Imipenem or Meropenem Carbapenemase-Producing Acinetobacter baumannii Utilizing the Hollow-Fiber Infection Model, ECCMID. Poster 02037."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jac\/dkg097","article-title":"Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii","volume":"51","author":"Conejo","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e0031223","DOI":"10.1128\/aac.00312-23","article-title":"In vitro pharmacokinetics\/pharmacodynamics of the beta-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex","volume":"68","author":"Tanudra","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jgar.2022.05.011","article-title":"In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance","volume":"30","author":"Findlay","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"104940","DOI":"10.1016\/j.ejps.2019.05.018","article-title":"Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii","volume":"136","author":"Jaruratanasirikul","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1128\/AAC.00342-13","article-title":"Pharmacodynamics modeling to optimize dosage regimens of sulbactam","volume":"57","author":"Jaruratanasirikul","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jac\/dkad032","article-title":"In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime\/avibactam, ampicillin\/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii","volume":"78","author":"Gill","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s10156-012-0431-6","article-title":"Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery","volume":"18","author":"Yokoyama","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_60","first-page":"2296","article-title":"In vitro pharmacodynamics of human-simulated exposures of ampicillin\/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii","volume":"68","author":"Housman","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1093\/cid\/ciad096","article-title":"The pharmacokinetics\/pharmacodynamic relationship of durlobactam in combination with sulbactam in in vitro and in vivo infection model systems versus Acinetobacter baumannii-calcoaceticus complex","volume":"76","author":"Bhavnani","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/jac\/dkae229","article-title":"Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy","volume":"79","author":"Abouelhassan","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_63","unstructured":"Clinical and Laboratory Standards Institute (2024, February 19). Acinetobacter baumannii Ampicillin\/Sulbactam Breakpoint Working Group Presentation. Presented 22 January 2024. Available online: https:\/\/app.smartsheet.com\/b\/publish?EQBCT=d95488fe530f46799bcc71ed48ce4029."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1128\/AAC.01669-16","article-title":"Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused by Acinetobacter baumannii","volume":"60","author":"Jaruratanasirikul","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e02534-19","DOI":"10.1128\/AAC.02534-19","article-title":"In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016 and 2017","volume":"64","author":"McLeod","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/AAC.01665-09","article-title":"Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/cid\/ciu706","article-title":"Update on Acinetobacter species: Mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options","volume":"59","author":"Castanheira","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jgar.2013.07.001","article-title":"Can ampicillin\/sulbactam resistance in Acinetobacter baumannii be predicted accurately by disk diffusion?","volume":"1","author":"Viana","year":"2013","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkx464","article-title":"Reporting antimicrobial susceptibilities and resistance phenotypes in Acinetobacter spp: A nationwide proficiency study","volume":"73","author":"Tomas","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/ciad094","article-title":"Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections","volume":"76","author":"Shields","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2217\/cer-2018-0037","article-title":"Meropenem\/colistin versus meropenem\/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia","volume":"7","author":"Khalili","year":"2018","journal-title":"J. Comp. Eff. Res."},{"key":"ref_72","first-page":"206","article-title":"Interim study: Comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin\/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter","volume":"17","author":"Mosaed","year":"2018","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_73","first-page":"269","article-title":"Comparison of intravenous ampicillin-sulbactam plus nebulized colistin with intravenous colistin plus nebulized colistin in treatment of ventilator associated pneumonia caused by multi drug resistant Acinetobacter baumannii: Randomized open label trial","volume":"18","author":"Pourheidar","year":"2019","journal-title":"Iran. J. Pharm. Res. Fall"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious diseases society of america 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s40121-021-00541-4","article-title":"Contemporary perspective on the treatment of Acinetobacter baumannii infections: Insights from the society of infectious diseases pharmacists","volume":"10","author":"Griffith","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_77","unstructured":"(2026, April 10). SENTRY Antimicrobial Surveillance Program. JMI Laboratories. Available online: https:\/\/sentry-mvp.jmilabs.com."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jgar.2024.01.019","article-title":"In vitro antimicrobial susceptibility data of global meropenem-resistant Acinetobacter baumannii isolates causing pneumonia: Data from the antimicrobial testing leadership and surveillance program, 2014\u20132021, and re-estimations of susceptibility breakpoints and appropriate dosages of important antibiotics for pneumonia treatment","volume":"36","author":"Hsueh","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2014.02.012","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models","volume":"43","author":"Yokoyama","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/jac\/dkae218","article-title":"Ampicillin-sulbactam against Acinetobacter baumannii infections: Pharmacokinetic\/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations","volume":"79","author":"Abouelhassan","year":"2026","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Guler","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e0169823","DOI":"10.1128\/aac.01698-23","article-title":"Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)","volume":"68","author":"Miller","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkaa208","article-title":"In vitro activity of sulbactam\/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii","volume":"75","author":"Seifert","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Principe, L., Di Bella, S., Conti, J., Perilli, M., Piccirilli, A., Mussini, C., and Decorti, G. (2022). Acinetobacter baumannii resistance to sulbactam\/durlobactam: A systematic review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121793"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e0066523","DOI":"10.1128\/aac.00665-23","article-title":"Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii","volume":"67","author":"Moussa","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14787210.2024.2440018","article-title":"Unraveling sulbactam-durlobactam: Insights into its role in combating infections caused by Acinetobacter baumannii","volume":"23","author":"Fu","year":"2025","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): A randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): A randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e0162724","DOI":"10.1128\/aac.01627-24","article-title":"A microbiological and structural analysis of the interplay between sulbactam\/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp","volume":"69","author":"Veeraraghavan","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e0080023","DOI":"10.1128\/aac.00800-23","article-title":"In vivo dose response and efficacyof the \u03b2-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex","volume":"68","author":"Tanudra","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","unstructured":"US Food and Drug Administration (2023, January 8). FDA briefingdocument: NDA 216974, Drug Name: Sulbactam-durlobactam for injection. Applicant: Entasis Therapeutics, Inc. Proceedings of the Antimicrobial Drugs Advisory Committee Meeting, Advisory Committee Meeting, Virtual."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e01089-18","DOI":"10.1128\/AAC.01089-18","article-title":"Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"ofaf250","DOI":"10.1093\/ofid\/ofaf250","article-title":"Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017\u20132022)","volume":"12","author":"Sader","year":"2025","journal-title":"Forum Infect Dis"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e0048524","DOI":"10.1128\/aac.00485-24","article-title":"Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data","volume":"69","author":"Cammarata","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"106776","DOI":"10.1016\/j.ijantimicag.2023.106776","article-title":"Activity of aztreonam\/avibactam against metallo-\u03b2-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 \u03b2-lactamase in Escherichia coli","volume":"61","author":"Livermore","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"ofad276","DOI":"10.1093\/ofid\/ofad276","article-title":"An NDM-producing Escherichia coli clinical isolate exhibiting resistance to cefiderocoland the combination of ceftazidime-avibactam and aztreonam: Another step toward pan-\u03b2-lactam resistance","volume":"10","author":"Simner","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cmi.2024.10.012","article-title":"Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocoland aztreonam-avibactam-resistant isolates","volume":"31","author":"Nordmann","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/cid\/ciae229","article-title":"Correction to: The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?","volume":"79","author":"Aitken","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/AAC.04819-14","article-title":"Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli","volume":"59","author":"Thulin","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jac\/dkad061","article-title":"In vitro activity of cefepime\/zidebactam and cefepime\/taniborbactam against aztreonam\/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates","volume":"78","author":"Nordmann","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"ofae140","DOI":"10.1093\/ofid\/ofae140","article-title":"Clinical outcomes for patients with monomicrobial vs. polymicrobial Acinetobacter baumannii-calcoaceticus complex infections treated with sulbactam-durlobactam or colistin: A subset analysis from a phase 3 clinical trial","volume":"11","author":"McLeod","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e0044023","DOI":"10.1128\/aac.00440-23","article-title":"In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e0154324","DOI":"10.1128\/aac.01543-24","article-title":"Restoring ceftolozane susceptibility: A role for diazabicyclooctane \u03b2-lactamase inhibitors?","volume":"69","author":"Dorazio","year":"2025","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/4\/449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:13:37Z","timestamp":1776773617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/4\/449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":104,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["pathogens15040449"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15040449","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}